Morningstar

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Johnson & Johnson (NYSE: JNJ) will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of ...
Seeking Alpha

J&J wins FDA nod for Tecnis PureSee intraocular lens

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...
Hosted on MSN

FDA approves Tecnis PureSee lens to cut glare risk

Johnson & Johnson has gained FDA approval for its Tecnis PureSee intraocular lens, the first extended depth-of-focus lens designed to maintain contrast sensitivity while minimizing glare and halos.
Healio

PureSee IOL demonstrates quality distance, intermediate vision

Please provide your email address to receive an email when new articles are posted on . The real-world observational study included 293 patients. The lens is designed to extend range of vision, ...
AOL

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

“With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option that reflects our commitment to innovation, visual quality, and patient ...